DYRK

DYRK Related Products (30):

By Effects:	Inhibitors (28) Degrader (1)

Cat. No.	Product Name	Effect	Purity

HY-111380

EHT 1610	Inhibitor	98.16%
EHT 1610 is a potent inhibitor of DYRK, with IC₅₀s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis^-.

HY-100464

tBID	Inhibitor	99.03%
tBID is a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2) with an IC₅₀ of 0.33 µM.

HY-15838

ID-8	Inhibitor	99.92%
ID-8 is an inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase (DYRK). ID-8 sustains embryonic stem cell (ESC) self-renewal and pluripotency. ID-8 enhances Wnt-mediated hESC survival and proliferation via inhibition of DYRKs.

HY-110320

LDN-209929 dihydrochloride	Inhibitor	≥99.0%
LDN-209929 dihydrochloride is a potent and selective haspin kinase inhibitor (IC₅₀=55 nM) with180-fold selectivity verses DYRK2 (IC₅₀=9.9 μM). LDN-209929 is a optimized analogue of LDN-192960 (HY-13455).

HY-117049

Leucettine L41	Inhibitor	98.70%
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3 (IC₅₀s = 0.04, 0.035, 0.015, and 4.5 µM, respectively). Leucettine L41 prevents lipid peroxidation and the accumulation of reactive oxygen species (ROS) induced by Aβ_25-35 in the hippocampus in a mouse model of Alzheimer’s disease-like toxicity. Leucettine L41 also prevents memory deficits induced by Aβ_25-35 in the same model.

HY-N0737AR

Harmine (Standard)	Inhibitor
Harmine (Standard) is the analytical standard of Harmine. This product is intended for research and analytical applications. Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM.

HY-159496

Dyrk1A-IN-10	Inhibitor
Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar.

HY-119607

DYRKi	Inhibitor
DYRKi is an inhibitor of DYRK1 and DYRK1B with IC₅₀ values of 3.7 µM and 90 nM, respectively, which is used as a potent antagonist of Hh/Gli signaling. DYRKi impairs SMO-dependent and SMO-independent oncogenic GLI activity in human medulloblastoma cells. DYRKi is promising for research of HH/GLI-associated cancers.

HY-144290

ARN25068	Inhibitor	99.66%
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation.

HY-13455A

LDN-192960 hydrochloride	Inhibitor	99.78%
LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC₅₀s of 10 nM and 48 nM, respectively.

HY-128439

BT173	Inhibitor	98.71%
BT173 is a potent homeodomain interacting protein kinase 2 (HIPK2) inhibitor. BT173 binds to HIPK2 does not inhibit HIPK2 kinase activity but rather, interfered allosterically with the ability of HIPK2 to associate with Smad3. BT173 attenuates renal fibrosis through suppression of the TGF-β1/Smad3 pathway.

HY-147060

Dyrk1A-IN-3	Inhibitor	99.96%
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC₅₀=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease.

HY-U00439

Protein kinase inhibitor 1	Inhibitor	≥99.0%
Protein kinase inhibitor 1 is a novel inhibitor of HIPK2 with an IC₅₀ of 74 nM and K_d of 9.5 nM.

HY-117608

ML 315	Inhibitor
ML 315 is a selective dual inhibitor of CDK and DYRK with IC₅₀s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research.

HY-117608A

ML 315 hydrochloride	Inhibitor	98.75%
ML 315 is a selective dual inhibitor of CDK and DYRK with IC₅₀s of 68 nM and 282 nM, respectively. ML 315 is used in cancer and neurological disease research.

HY-122665A

HTH-01-091 TFA	Inhibitor	99.48%
HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research.

HY-125202

KuWal151	Inhibitor
KuWal151 is a CLK1, CLK2 and CLK4 inhibitor with a high selectivity margin towards DYRK kinases. KuWal151 has potent antiproliferative activity in an array of cultured cancer cell lines.

HY-155723

Leucettinib-92	Inhibitor
Leucettinib-92 (compound 92) is an inhibitor of DYRK/CLK kinase, The IC₅₀s are 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM (CLK3), 124 nM (DYRK1A), 204 nM (DYRK1B), 0.16 μM (DYRK2), respectively. 1.0 μM (DYRK3), 0.52 μM (DYRK4), 2.78 μM (GSK3).

HY-161014

DYRK2-IN-1	Inhibitor
DYRK2-IN-1 (Compd 54) is an orally bioavailable DYRK2 inhibitor, with an IC₅₀ of 14 nM. DYRK2-IN-1 (Compd 54) can be used in the study of prostate cancer.

HY-P3812

Woodtide
Woodtide is a substrate for the DYRK (DYRK) family of kinases whose sequence is based on that around the DYRK phosphorylation site in FKHR.

Name
Email *

	Sorry, but the email address you supplied was invalid.